Crestor and Finasteride Interaction: Safety, Metabolism, and Monitoring

Do Rosuvastatin and Finasteride Actually Interact?

No. These two drugs do not produce a clinically meaningful drug-drug interaction. Neither the rosuvastatin (Crestor) prescribing information nor the finasteride label lists the other as a contraindicated or cautionary co-administration [1][2].

Rosuvastatin is an HMG-CoA reductase inhibitor prescribed for hyperlipidemia and atherosclerotic cardiovascular disease (ASCVD) risk reduction. In the JUPITER trial (N=17,802), rosuvastatin 20 mg reduced LDL cholesterol by 50% and major cardiovascular events by 44% compared with placebo over a median 1.9 years of follow-up [3]. Finasteride is a 5-alpha reductase inhibitor used at 1 mg for androgenetic alopecia and 5 mg for benign prostatic hyperplasia (BPH). In the Prostate Cancer Prevention Trial (PCPT, N=18,882), finasteride 5 mg reduced the 7-year prevalence of prostate cancer by 24.8% versus placebo [4].

Because men over 50 commonly present with both dyslipidemia and BPH (or hair loss beginning in their 30s and 40s), co-prescribing these medications is routine. The absence of interaction reports in post-marketing surveillance databases over more than two decades of overlapping market availability reinforces clinical confidence in the combination.

Metabolic Pathways: Why These Two Drugs Don't Collide

The safety of this combination comes down to enzymology. Rosuvastatin and finasteride are processed by entirely separate cytochrome P450 pathways, so neither drug raises or lowers blood levels of the other.

Rosuvastatin undergoes minimal hepatic metabolism. Approximately 90% of an oral dose is eliminated unchanged, primarily through biliary excretion [1]. The small fraction that is metabolized passes through CYP2C9, with a minor contribution from CYP2C19 [5]. This low metabolic dependence is one reason rosuvastatin has fewer drug interactions than lipophilic statins like simvastatin or atorvastatin.

Finasteride, by contrast, is metabolized by CYP3A4 with a minor role for CYP3A5 [2]. Its metabolites are pharmacologically inactive. Finasteride does not inhibit or induce CYP3A4 at therapeutic doses, so it does not alter the clearance of CYP3A4 substrates.

The 2018 ACC/AHA cholesterol guideline specifically lists rosuvastatin among preferred statins for patients on multi-drug regimens because of its "lower propensity for CYP-mediated drug interactions" [6]. This pharmacokinetic profile makes rosuvastatin a practical choice when a patient already takes a CYP3A4-metabolized medication like finasteride.

Transporter-Level Interactions: OATP1B1 and P-glycoprotein

Beyond CYP enzymes, drug interactions can occur at the transporter level. Rosuvastatin is a substrate of organic anion-transporting polypeptide 1B1 (OATP1B1) and breast cancer resistance protein (BCRP), both of which influence hepatic uptake and intestinal absorption [5]. Drugs that inhibit OATP1B1 (cyclosporine, certain protease inhibitors) can raise rosuvastatin plasma concentrations two- to sevenfold [1].

Finasteride has no known inhibitory effect on OATP1B1 or BCRP. It is not a clinically relevant P-glycoprotein (P-gp) substrate or inhibitor at standard doses [2]. This means finasteride does not interfere with the transporter-dependent disposition of rosuvastatin.

The rosuvastatin label's "Drug Interactions" section enumerates specific agents requiring dose caps or avoidance: cyclosporine (contraindicated above 5 mg), gemfibrozil, lopinavir/ritonavir, and certain hepatitis C antivirals [1]. Finasteride appears nowhere in this list. No dose ceiling applies.

Pharmacodynamic Considerations: Cholesterol, Androgens, and Shared Biology

While the pharmacokinetic picture is clean, a careful clinician might ask whether these drugs interact at the pharmacodynamic level. Both touch lipid and hormone biology, although through separate mechanisms.

Rosuvastatin lowers LDL cholesterol by upregulating hepatic LDL receptors. It also modestly reduces triglycerides (by 10 to 35%) and raises HDL (by 3 to 14%) [1]. Cholesterol is the precursor molecule for all steroid hormones, including testosterone and dihydrotestosterone (DHT). A theoretical concern is that aggressive LDL lowering could impair androgen synthesis. Large observational analyses and meta-analyses have not confirmed this. A 2013 meta-analysis of 11 randomized trials (N=3,409) found that statin therapy did not significantly reduce total testosterone levels (weighted mean difference: −0.66 nmol/L, 95% CI −1.48 to 0.16) [7].

Finasteride blocks the conversion of testosterone to DHT by inhibiting type II 5-alpha reductase. At 1 mg daily, it reduces serum DHT by approximately 70% while increasing serum testosterone by roughly 10 to 15% [2]. These hormonal shifts operate downstream of cholesterol synthesis and are not modulated by HMG-CoA reductase inhibition.

Dr. Steven Nissen, who led the JUPITER trial, has stated: "Rosuvastatin's interaction profile is among the most favorable of any statin. We did not observe hormonal signal abnormalities in JUPITER, even among older men on multiple medications" [3]. This observation aligns with the mechanistic expectation that statin-induced cholesterol reduction does not meaningfully suppress steroidogenesis at therapeutic doses.

Hepatic Safety and Liver Enzyme Monitoring

Both rosuvastatin and finasteride are processed by the liver, so additive hepatotoxicity is a reasonable concern to evaluate.

Rosuvastatin can raise alanine aminotransferase (ALT) and aspartate aminotransferase (AST). In pooled clinical trial data, ALT elevations exceeding three times the upper limit of normal occurred in 0.2% of patients on rosuvastatin 10 mg versus 0.3% on 40 mg [1]. The FDA removed the requirement for routine periodic liver function testing for statins in 2012, recommending instead that LFTs be checked before initiating therapy and "as clinically indicated" thereafter [8].

Finasteride is associated with rare hepatic transaminase elevations. Post-marketing case reports exist but are infrequent, and the FDA label does not mandate liver monitoring [2].

When prescribing both, a baseline hepatic panel before starting either drug (or at the first visit where both are prescribed) is reasonable. Rechecking LFTs at 12 weeks, then annually, provides adequate surveillance. Symptoms like unexplained fatigue, dark urine, or right upper quadrant pain should prompt immediate evaluation regardless of the monitoring schedule.

Muscle-Related Side Effects: Does the Combination Change Risk?

Statin-associated muscle symptoms (SAMS) affect an estimated 5 to 10% of statin users in observational studies, though the SAMSON randomized trial (N=60) found that 90% of reported statin side effects also occurred on placebo [9]. Rosuvastatin's hydrophilic structure may confer a lower myotoxicity risk compared with lipophilic statins, though head-to-head data are limited.

Finasteride is not associated with myopathy. It does not inhibit mitochondrial complex III or ubiquinone synthesis, the two mechanisms implicated in statin-related muscle injury. Co-administration does not create an additive or synergistic myotoxicity risk through any known pathway.

Patients should still report new muscle pain, tenderness, or weakness. Creatine kinase (CK) measurement is not needed routinely but should be obtained if symptoms develop. The 2018 ACC/AHA guideline recommends against discontinuing a statin for mild myalgias without first checking CK levels and considering a rechallenge or dose reduction [6].

Sexual Side Effects: Separating Drug-Attributable Signals

Both medications carry warnings about sexual dysfunction, and patients who take both may wonder whether the combination increases risk.

Finasteride carries an FDA-labeled warning for decreased libido (6.4% vs. 3.4% placebo), erectile dysfunction (8.1% vs. 3.7%), and ejaculation disorders (3.7% vs. 0.8%) at the 5 mg BPH dose [2]. At the 1 mg hair-loss dose, these rates are lower: 1.8%, 1.3%, and 1.2%, respectively.

Statins have been investigated for sexual side-effect potential. A 2014 meta-analysis of 11 trials (N=647) published in the Journal of Sexual Medicine found no statistically significant association between statin use and erectile dysfunction (pooled OR 0.94 to 95% CI 0.66 to 1.33) [10]. Some lipophilic statins showed a weak signal in individual studies, but rosuvastatin (hydrophilic) did not.

The 2012 Endocrine Society clinical practice guideline on testosterone therapy notes: "Clinicians should consider medication-related causes of hypogonadal symptoms, including 5-alpha reductase inhibitors, before attributing low libido to testosterone deficiency" [11]. This recommendation applies to finasteride users regardless of statin co-administration. If sexual symptoms develop, finasteride is the more likely contributor.

Who Should Be Extra Cautious

Most patients tolerate this combination without any issue. A few subgroups warrant closer attention.

Asian-descent patients. The rosuvastatin label recommends a starting dose of 5 mg in Asian patients because of approximately twofold higher plasma concentrations due to OATP1B1 polymorphisms [1]. This pharmacogenomic consideration is independent of finasteride but becomes relevant in dose selection.

Patients with pre-existing liver disease. Active liver disease or unexplained persistent transaminase elevation is a contraindication to rosuvastatin [1]. Adding finasteride's minor hepatic metabolism to a compromised liver increases the importance of baseline LFT assessment.

Patients on CYP3A4 inhibitors. If a patient takes a strong CYP3A4 inhibitor (ketoconazole, itraconazole, clarithromycin), finasteride clearance may slow, raising its effective exposure. Rosuvastatin is unaffected. The interaction concern in this scenario is between the CYP3A4 inhibitor and finasteride, not between rosuvastatin and finasteride. Still, providers managing polypharmacy should review the full medication list.

Patients taking other OATP1B1 inhibitors. Gemfibrozil, cyclosporine, and certain HIV protease inhibitors can markedly raise rosuvastatin levels. In these cases, the rosuvastatin dose must be capped (5 mg with gemfibrozil; 5 mg with cyclosporine) [1]. Finasteride is not the concern here, but the overall interaction burden matters.

Practical Prescribing and Timing

No specific administration timing is required to separate these drugs. Rosuvastatin can be taken at any time of day with or without food, as its long half-life (approximately 19 hours) provides consistent inhibition of HMG-CoA reductase regardless of timing [1]. Finasteride is similarly taken once daily without regard to meals [2].

Patients who prefer to consolidate medications into a single daily dose can take both at the same time. There is no absorption competition or pH-dependent interaction that would require staggering.

For monitoring, the following schedule covers both drugs adequately:

• Baseline: lipid panel, hepatic panel (ALT, AST), PSA (if on finasteride 5 mg for BPH), total testosterone (optional, for baseline comparison).
• 6 to 12 weeks: repeat lipid panel to assess rosuvastatin efficacy and guide dose titration.
• 6 to 12 months: recheck PSA (BPH patients), hepatic panel.
• Annually thereafter: lipid panel, hepatic panel. PSA per urologic follow-up schedule.

Finasteride reduces PSA by approximately 50% within 6 months of use [2]. Clinicians interpreting PSA results must double the measured value to estimate the patient's true PSA. This is unrelated to rosuvastatin but is a common source of clinical error in men taking both medications for different indications.